GSK and SiranBio Enter $1 Billion Licensing Agreement for Abdominal Fat Reduction siRNA 'SA030'
A New Breakthrough in the Obesity Treatment Market
Global pharmaceutical company GlaxoSmithKline (GSK) has partnered with Chinese biopharmaceutical company SiranBio to develop an innovative therapy for reducing abdominal fat. The companies have entered into an agreement to acquire global development and commercialization rights (excluding Greater China) for 'SA030,' a novel small interfering RNA (siRNA) drug candidate that has the potential to be a game-changer in the metabolic disease field. While glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide from Novo Nordisk and tirzepatide from Eli Lilly currently dominate the market, challenges remain in addressing muscle loss and the selective removal of visceral abdominal fat. This collaboration represents GSK's strategic decision to target visceral abdominal fat safely, going beyond simple weight loss, as it is a fundamental cause of cardiovascular and metabolic diseases.
The Differentiating Technology of ALK7-Targeting siRNA
'SA030' is based on small interfering RNA (siRNA) technology, which inhibits the expression of specific genes within cells, and selectively inhibits activin receptor-like kinase 7 (ALK7) protein. ALK7 is a key receptor involved in fat accumulation and metabolic regulation in the body. By inhibiting it, muscle mass can be maintained while effectively breaking down visceral fat. In particular, SiranBio's in-house developed fat cell-targeted delivery platform, 'STORK-F,' is used to ensure that the drug is precisely delivered only to abdominal fat tissue. It is expected to be a powerful next-generation alternative that can overcome the sarcopenia side effects experienced by existing GLP-1 therapies, reduce cardiovascular risk, and improve patients' metabolic function.
Financial Details of the Agreement
The total transaction size of this agreement is up to $1.06 billion (approximately 1.45 trillion Korean Won), and GSK has agreed to pay an upfront payment of $55 million. Subsequently, SiranBio will receive additional milestone payments of up to $1.005 billion, as well as royalties based on sales, depending on the success of clinical development, regulatory approval, and commercialization. The new drug candidate 'SA030' is currently in Phase 1 clinical trials, targeting overweight and obese subjects, to verify its safety and tolerability. Until the completion of the initial Phase 1 trials, SiranBio will lead the development, and GSK will be fully responsible for subsequent global clinical development and commercialization processes.
Impact on the Global Metabolic Disease Market
This deal clearly demonstrates that the paradigm of the obesity treatment market is evolving from simple weight loss to a focus on cardiovascular and metabolic disease management with an emphasis on organ protection. Visceral fat accumulation is a major cause of metabolic inflammation, leading to fatty liver, chronic kidney disease, and chronic lung disease. Currently, Arrowhead Pharmaceuticals' 'ARO-ALK7' is leading the field with a Phase 1/2a trial, and OliX is also preparing a competing pipeline. Through this acquisition, GSK is expected to secure an independent position in the obesity and metabolic disease market, which is projected to grow to $130 billion in the future, by creating combination therapies with existing metabolic and cardiovascular drugs.
GSK's acquisition of SA030 is a mid- to long-term strategic move to overcome the limitations of existing GLP-1 therapies, specifically muscle loss, in the obesity and metabolic disease market, which is projected to reach $130 billion. This candidate, currently in Phase 1 clinical trials, utilizes the STORK-F fat cell-targeted delivery platform to selectively reduce visceral abdominal fat and reduce cardiovascular metabolic chronic inflammation, demonstrating new clinical value. Arrowhead Pharmaceuticals' ARO-ALK7, a competing pipeline targeting the same ALK7, is currently in Phase 1/2a trials and has demonstrated excellent safety and fat reduction efficacy, suggesting that competition for the best-in-class drug in this class will intensify. The upfront payment of $55 million and milestone payments of up to $1.005 billion reflect the high value of this early-stage asset, and the acquisition of clinical data in the future will maximize the value of the pipeline for combination therapies in the treatment of metabolic diseases.